Company Filing History:
Years Active: 2006
Title: Wagner Monteiro Cintra: Innovator in Cardiac Treatment
Introduction
Wagner Monteiro Cintra is a notable inventor based in Rio de Janeiro, Brazil. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with therapeutic properties. His work focuses on innovations that can improve cardiac health and muscle function.
Latest Patents
Wagner Monteiro Cintra holds a patent for a compound known as Thienylhydrazon, which exhibits digitalis-like properties. This invention is characterized by a specific formula that includes various chemical groups, making it a promising candidate for treating congestive heart failure and muscle fatigue. The compound, LASSBio-294, is noted for producing positive inotropic effects on both cardiac and skeletal muscle, while lacking the toxic effects commonly associated with digitalis glycosides.
Career Highlights
Wagner is affiliated with the University System of Maryland, where he continues to engage in research and development. His innovative approach to synthesizing compounds has positioned him as a key figure in the pharmaceutical industry. His work not only contributes to academic knowledge but also has practical implications for patient care.
Collaborations
Wagner has collaborated with esteemed colleagues such as Roberto Takashi Sudo and Edson X Albuquerque. These partnerships enhance the research environment and foster the exchange of ideas, leading to further advancements in their respective fields.
Conclusion
Wagner Monteiro Cintra's contributions to cardiac treatment through his innovative patent demonstrate the potential for new therapies in medicine. His work exemplifies the intersection of research and practical application, paving the way for future advancements in healthcare.